Bio-Rad Laboratories, Inc. (BIO)
NYSE: BIO · Real-Time Price · USD
268.63
-2.67 (-0.98%)
Feb 23, 2026, 10:29 AM EST - Market open
Bio-Rad Laboratories Stock Forecast
Stock Price Forecast
The 4 analysts that cover Bio-Rad Laboratories stock have a consensus rating of "Strong Buy" and an average price target of $358.5, which forecasts a 33.45% increase in the stock price over the next year. The lowest target is $310 and the highest is $409.
Price Target: $358.5 (+33.45%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 30, 2025.
Analyst Ratings
The average analyst rating for Bio-Rad Laboratories stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $350 → $375 | Strong Buy | Maintains | $350 → $375 | +39.60% | Oct 30, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $265 → $340 | Hold | Maintains | $265 → $340 | +26.57% | Oct 30, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $387 → $409 | Buy | Maintains | $387 → $409 | +52.25% | Aug 1, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $245 → $265 | Hold | Maintains | $245 → $265 | -1.35% | Aug 1, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $260 → $245 | Hold | Maintains | $260 → $245 | -8.80% | Jun 9, 2025 |
Financial Forecast
Revenue This Year
2.64B
from 2.58B
Increased by 2.31%
Revenue Next Year
2.73B
from 2.64B
Increased by 3.10%
EPS This Year
10.25
from 27.85
Decreased by -63.19%
EPS Next Year
11.38
from 10.25
Increased by 10.97%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 2.8B | 2.9B | ||
| Avg | 2.6B | 2.7B | ||
| Low | 2.5B | 2.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 7.5% | 9.3% | ||
| Avg | 2.3% | 3.1% | ||
| Low | -1.8% | -2.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 11.40 | 13.05 | ||
| Avg | 10.25 | 11.38 | ||
| Low | 8.08 | 8.54 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | -59.1% | 27.3% | ||
| Avg | -63.2% | 11.0% | ||
| Low | -71.0% | -16.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.